(Vienna, 20.09.2021) CONGRATULATIONS to Benjamin Salzer, PhD, and Charlotte Zajc, PhD, from our Christian Doppler Laboratory for Next Generation CAR T Cells! Both have won with their publication resulting from their doctoral thesis a first place at the Life Science Research Awards Austria 2021 – Benjamin Salzer (St. Anna Children's…
Benjamin Salzer and Charlotte Zajc win Life Science Research Awards
Kaan Boztug awarded the "Işil Berat Barlan Award for Primary Immunodeficiency Diseases"
(Vienna, 03.09.2021) Congratulations! Assoc.-Prof. Kaan Boztug, MD, Scientific Director of the St. Anna Children's Cancer Research Institute and Director of the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, has been awarded the Işil Berat Barlan Award for his outstanding research in the field of primary immunodeficiencies, which will be…
Bone marrow metastases for the first time analyzed cell by cell
(02.09.2021) When childhood nerve tumors, so-called neuroblastomas, form metastases, they preferentially do so in the bone marrow. A study by St. Anna Children's Cancer Research Institute shows for the first time the exact cell composition of such metastases. This knowledge forms the basis for the development of therapy concepts that…
Childhood Cancer Awareness Month 2021 - St. Anna CCRI under the sign of the gold ribbon
(Vienna, 01.09.2021) With our research, we aim to strike childhood cancer at its roots. In Austria, about 200 children and 100 adolescents are diagnosed with cancer each year. Thanks to research and the resulting major advances in treatment, 85% of affected children and adolescents are cured. However, about 30 children…
“Our results can have a direct impact on a child’s life”
(Vienna, 17.8.2021) Together with colleagues, Artem Kalinichenko (37) discovered a novel gene defect causing a life-threatening immune disorder. Profiled as a YoungStar by St. Anna Children’s Cancer Research Institute (St. Anna CCRI), the scientist explains how to form a good hypothesis and under which circumstances he acquires aha-experiences. Artem Kalinichenko,…
Four FWF Stand Alone Projects recently approved at St. Anna CCRI
(12.08.2021) The Austrian Science Fund (FWF) awards four scientists from St. Anna Children’s Cancer Research Institute (St. Anna CCRI) with Stand Alone Grants, each of which is worth almost € 400,000. Congratulations to the grantees Kaan Boztug, Eva König, Thomas Lion, and Eleni Tomazou! Getting a Stand-Alone Project approved from…
Survivorship Passport: For a better life after childhood cancer
(Vienna, 12.7.2021) EU funds research project to improve long-term follow-up care for childhood cancer survivors with 4 million euros. In Europe, 35,000 children and adolescents are diagnosed with cancer every year, about 300 of them in Austria. Thanks to better cancer treatments, in recent decades the survival rate has increased…
“1000 Ideas” to boost childhood cancer research: St. Anna CCRI earns two grants in competitive FWF program
(Vienna, 29.06.2021) Two projects from St. Anna Children’s Cancer Research Institute (St. Anna CCRI) receive funding from the “1000 Ideas Programme” of the Austrian Science Fund (FWF). The aim of this program is to support daring and original research ideas that lie outside the current scientific understanding. In the second…
Do you speak immunology? A new language for congenital immune disorders
(Vienna, 30.06.2021) A detailed vocabulary to identify and explore rare, congenital immune disorders around the world? That is exactly what is now available thanks to a new study led by the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna and the University Medical Center Groningen. Congenital immune disorders…
Nerve tumor in children: study identifies better tolerable chemotherapy without loss of efficacy
(Vienna, 21.06.2021) The initial chemotherapy of aggressive childhood nerve tumors, so-called high-risk neuroblastomas, is crucial for ultimate survival. It has now been shown that the chemotherapy regimen used by the European Neuroblastoma Study Group is equally efficacious but better tolerated than a highly effective regimen from the US. This was…